Two UK developers report progress with Parkinson's drugs; Discovery Labs gets $35M financing line;

 @FierceBiotech: Big Pharma coalition will pool data on failed Alzheimer's drugs. Report | Follow @FierceBiotech

 @JohnCFierce: Ain't it cool science: Plastic antibodies used to "cure "mice of bee venom. Report | Follow @JohnCFierce

> Shares of the UK's Phytopharm shot up after the developer announced that the FDA had approved a mid-stage trial of its lead Parkinson's drug. Oxford BioMedica, meanwhile, reported that two year data on its gene therapy for Parkinson's continued to demonstrate efficacy. CEO John Dawson says that the new data will help the company conclude a licensing pact. Story

> Kingsbridge Capital has committed $35 million to a new credit facility for the troubled Discovery Laboratories. The deal gives Discovery the right to tap the credit line by selling shares to Kingsbridge at a conversion rate of $0.4459. Discovery release

> Teva Pharmaceutical is bumping its stake in Andromeda Biotech, which is developing a new therapy for juvenile Type 1 diabetes. Report

> On Friday Aastrom Biosciences offered positive interim data on its experimental therapy for critical limb ischemia. Story

> Questcor Pharmaceuticals says that the PDUFA date for its supplemental new drug application to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010. Questcor release

And Finally... How is it that some people who apparently freeze to death, with no heart rate or respiration for extended periods, can be brought back to life with no long-term negative health consequences? Report

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.